Drug Trial Radar · NCT05453903
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
196
Actual
Start
Oct 4, 2022
Primary completion
Oct 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).
Conditions
- Leukemia, Myeloid, Acute
Interventions
BleximenibDrug
Participants will receive bleximenib.
Venetoclax (VEN)Drug
Participants will receive VEN.
Azacitidine (AZA)Drug
Participants will receive AZA.
CytarabineDrug
Participants will receive cytarabine.
Daunorubicin or IdarubicinDrug
Participants will receive daunorubicin or idarubicin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to 3 Years 3 months
- Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 3 Years 3 months
- Number of Participants with Dose-limiting Toxicity (DLT)Time frame: End of Cycle 1 (28 days)
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
City of Hope
Duarte, California
Massachusetts General Hospital
Boston, Massachusetts
Albert Einstein College Of Medicine
New York, New York
Novant Health
Charlotte, North Carolina
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina
MD Anderson
Houston, Texas
Monash Medical Centre
Clayton, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Westmead Hospital
Westmead, Australia
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, Canada
Institut Paoli Calmettes
Marseille, France
Chu Rennes Hopital Pontchaillou
Rennes, France
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
CHU de Tours - Hôpital de Bretonneau
Tours, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Universitatsklinikum Ulm
Ulm, Germany
Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
Bologna, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, Italy
Hosp Clinic de Barcelona
Barcelona, Spain
Hosp. de La Santa Creu I Sant Pau
Barcelona, Spain
Hosp Univ Vall D Hebron
Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
Clinica Univ. de Navarra
Pamplona, Spain
University College London Hospitals NHSFT
London, United Kingdom
Christie Hospital NHS Trust
Manchester, United Kingdom
Oxford University Hospitals NHS Trust
Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.